← Explorer/Network

Possible estuary-associated syndrome: symptoms, vision, and treatment.

Shoemaker RC, Hudnell HK2001Environmental Health PerspectivesJournal Article
10.1289/ehp.01109539PubMedFree full text
CardiovascularEndocrine (ADH/ACTH/MSH)GastrointestinalHypothalamic-PituitaryImmune/InnateMusculoskeletalNeurologicalOcularRespiratory/Sinus
ActinomycetesBacterial EndotoxinsIndoor Mold (Stachybotrys, Aspergillus, etc.)MycotoxinsVolatile Organic Compounds (VOCs)Water-Damaged Buildings (WDB)

Abstract

The human illness designated as possible estuarine-associated syndrome (PEAS) by the Centers for Disease Control and Prevention (CDC) has been associated with exposure to estuaries inhabited by toxin-forming dinoflagellates, including members of the fish-killing toxic Pfiesteria complex (TPC), Pfiesteria piscicida and Pfiesteria shumwayae. Humans may be exposed through direct contact with estuarine water or by inhalation of aerosolized or volatilized toxin(s). The five cases reported here demonstrate the full spectrum of symptoms experienced during acute and chronic stages of this suspected neurotoxin-mediated illness. The nonspecific symptoms most commonly reported are cough, secretory diarrhea, headache, fatigue, memory impairment, rash, difficulty in concentrating, light sensitivity, burning skin upon water contact, muscle ache, and abdominal pain. Less frequently encountered symptoms are upper airway obstruction, shortness of breath, confusion, red or tearing eyes, weakness, and vertigo. Some patients experience as few as four of these symptoms. The discovery that an indicator of visual pattern-detection ability, visual contrast sensitivity (VCS), is sharply reduced in affected individuals has provided an objective indicator that is useful in diagnosing and monitoring PEAS. VCS deficits are present in both acute and chronic PEAS, and VCS recovers during cholestyramine treatment coincident with symptom abatement. Although PEAS cannot yet be definitively associated with TPC exposure, resolution with cholestyramine treatment suggests a neurotoxin-mediated illness.

Key Biomarkers

Alpha Melanocyte Stimulating Hormone (MSH)Immunoglobulin E (IgE)LeptinMatrix Metalloproteinase 9 (MMP9)Vascular Endothelial Growth Factor (VEGF)Visual Contrast Sensitivity (VCS)

Symptom Clusters

Dermatological: rash, burning skin upon water contactGastrointestinal: secretory diarrhea, abdominal painGeneral: fatigueMusculoskeletal: muscle ache, weaknessNeurological: memory impairment, difficulty concentrating, confusion, vertigo, headacheOcular: light sensitivity, red or tearing eyesRespiratory: cough, upper airway obstruction, shortness of breath

Cited By (15)

  • Chronic biotoxin-associated illness: Multiple-system symptoms, a vision deficit, and effective treatmentNeurotoxicology and Teratology · 2005
  • Apartment residents' and day care workers' exposures to tetrachloroethylene and deficits in visual contrast sensitivity.Environmental Health Perspectives · 2002
  • Sick building syndrome (SBS) and exposure to water-damaged buildings: Time series study, clinical trial and mechanismsNeurotoxicology and Teratology · 2006
  • A time-series study of sick building syndrome: chronic, biotoxin-associated illness from exposure to water-damaged buildingsNeurotoxicology and Teratology · 2005
  • Association between spill-related exposure to fine particulate matter and peripheral motor and sensory nerve function among oil spill response and cleanup workers following the Deepwater Horizon oil spillJournal of Exposure Science & Environmental Epidemiology · 2023
  • Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatmentAnnals of Medicine and Surgery · 2024

Related Papers

  • Synergistic interaction in simultaneous exposure to Streptomyces californicus and Stachybotrys chartarumEnvironmental Health Perspectives · 2004 · 15 shared tags
  • Correction to “Maitotoxin induces biphasic interleukin-1β secretion and membrane blebbing in murine macrophages”Mol Pharmacol · 2004 · 15 shared tags
  • HUMAN VISUAL FUNCTION IN THE NORTH CAROLINA CLINICAL STUDYON POSSIBLE ESTUARY-ASSOCIATED SYNDROMEJournal of Toxicology and Environmental Health · 2001 · 15 shared tags
  • Cholestyramine protection against ochratoxin A toxicity: role of ochratoxin A sorption by the resin and bile acid enterohepatic circulationJournal of Food Protection · 1999 · 15 shared tags
  • In vitro and in vivo studies to assess the effectiveness of cholestyramine as a binding agent for fumonisinsMycopathologia · 2001 · 15 shared tags
  • Occurrence of Toxigenic Aspergillus versicolor Isolates and Sterigmatocystin in Carpet Dust from Damp Indoor EnvironmentsApplied and Environmental Microbiology · 2002 ·
Neurobehavioral effects of harmful algal bloom (HAB) toxins: a critical reviewJournal of the International Neuropsychological Society · 2005
  • Residential and Recreational Acquisition of Possible Estuary-Associated Syndrome: A New Approach to Successful Diagnosis and TreatmentEnvironmental Health Perspectives · 2001
  • Clearance of multiple antibiotic-resistant coagulase-negative staphylococci is selectively associated with higher circulating α-melanocyte stimulating hormone in patients evaluated for chronic inflammatory response syndromeFrontiers in Endocrinology · 2026
  • Atovaquone plus cholestyramine in patients coinfected withBabesia microti andBorrelia burgdorferi refractory to other treatmentAdvances in Therapy · 2006
  • Marine Neurotoxins: Envenomations and contact toxinsCurrent Treatment Options in Neurology · 2004
  • Prospects on behavioral studies of marine and freshwater toxinsNeurotoxicology and Teratology · 2005
  • Pfiesteria in Estuarine Waters: The question of health risksEnvironmental Health Perspectives · 2007
  • A letter of comment on "Human health effects of exposure to Pfiesteria piscicida: a review" by Swinker and colleaguesMicrobes and Infection · 2003
  • Assessment of visual contrast sensitivity in biotoxin-exposed individuals using four testing methodsAnnals of Medicine · 2026
  • References (16)

    • Learning and memory difficulties after environmental exposure to waterways containing toxin-producing Pfiesteria or Pfiesteria-like dinoflagellatesThe Lancet · 1998
    • Treatment of Chlordecone (Kepone) Toxicity with CholestyramineNew England Journal of Medicine · 1978
    • Prevention of nephrotoxicity of ochratoxin A, a food contaminantToxicology Letters · 1995
    • Whole-Bowel Irrigation As an Adjunct to the Treatment of Chronic, Relapsing Clostridium Difficile ColitisJournal of Clinical Gastroenterology · 1996
    • The influence of vision on computerized neurobehavioral test scores: A proposal for improving test protocolsNeurotoxicology and Teratology · 1996
    • PHARMACOKINETICS OF HALOGENATED HYDROCARBONSAnnals of the New York Academy of Sciences · 1979
    • Reduction in the body content of DDE in the mongolian gerbil treated with sucrose polyester and caloric restriction*1Toxicology and Applied Pharmacology · 1988
    • Treatment of persistent Pfiesteria-human illness syndromePubMed · 1998
    • Insidious effects of a toxic estuarine dinoflagellate on fish survival and human healthJournal of Toxicology and Environmental Health · 1995
    • Diagnosis of Pfiesteria-human illness syndromePubMed · 1997
    • New 'phantom' dinoflagellate is the causative agent of major estuarine fish killsNature · 1992
    • Effectiveness of cholestyramine in the detoxification of zearalenone as determined in miceBulletin of Environmental Contamination and Toxicology · 1995
    • Cholestyramine: Use as a New Therapeutic Approach for Chlordecone (Kepone) PoisoningScience · 1978
    • Multiple Relapses of Clostridium difficile-Associated Diarrhea in a Cancer Patient Successful Control with Long-Term Cholestyramine TherapyJournal of Pediatric Hematology/Oncology · 1992
    • A Model System for Studying the Bioavailability of Intestinally Administered Microcystin‐LR, A Hepatotoxic Peptide from the Cyanobacterium Microcystis aeruginosaPharmacology & Toxicology · 1989
    • Dietary cholestyramine reduces ochratoxin A-induced nephrotoxicity in the rat by decreasing plasma levels and enhancing fecal excretion of the toxinJournal of Toxicology and Environmental Health · 1998
    15 shared tags